Compare TG Therapeutics Inc (TGTX) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Toyota Motor Corp — how do they compare? TG Therapeutics Inc trades at $54.88 (market cap $8.16B), while Toyota Motor Corp trades at $184.8 (market cap $217.38B). The key difference: Toyota Motor Corp is far larger — about 26.6× TG Therapeutics Inc's market cap, and Toyota Motor Corp pays a 3.37% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Toyota Motor Corp for 116 Days on average.
| TGTX | TM | |
|---|---|---|
Market Cap | $8.16B | $217.38B |
Volume | 1,735,121 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $248.29 |
52-Week Low | $26.94 | $166.50 |
Typical Hold Time | 16 Days | 116 Days |
Enterprise Value | $8.37B | $410.96B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Toyota Motor trades at $184.84, up 1.06% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while delivering consistent earnings beats. Recent U.S. sales growth and electrification progress contrast with China market challenges and production disruptions from Thailand floods.
Toyota presents a value opportunity with solid profitability and market share gains, though technical weakness and regional sales pressures warrant caution. The company's electrification investments and strong U.S. position support long-term growth, while currency risks and competitive pressures remain key monitoring points for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
